<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907985</url>
  </required_header>
  <id_info>
    <org_study_id>112676</org_study_id>
    <nct_id>NCT00907985</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects</brief_title>
  <official_title>Double Blind, Double-dummy, Randomised, Placebo Controlled Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of drug A on its own and when it is
      given in combination with drug B on markers of brain activity. The study will

        1. Assess the effects of drug A and drug B on muscle movement after brain stimulation;

        2. Examine how the body handles (absorbs, distributes, breaks down and gets rid of) drug A
           and drug B when given in combination;

        3. Examine the safety of drug A and drug B when given together.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment; trial unlikely to reach completion
  </why_stopped>
  <start_date type="Actual">May 15, 2009</start_date>
  <completion_date type="Actual">June 10, 2010</completion_date>
  <primary_completion_date type="Actual">June 10, 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of the study treatments on Resting Motor Thresholds (rMT)</measure>
    <time_frame>Within 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety and tolerability of the combination of study treatments.</measure>
    <time_frame>Within 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>20</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Treatment sequence A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence A will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence B will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence C will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence D will receive single dose of placebo in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence E will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + placebo in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence F will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence G will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session A of part 2 and placebo + placebo in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence H will receive single dose of placebo part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + vofopitant 10 milligrams capsule in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence I will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence J</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence J will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence K</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence K will receive single dose of placebo in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + vofopitant 10 milligrams capsule in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence L will receive single dose of placebo in part 1, single doses of placebo + vofopitant 10 milligrams capsule in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence M</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence M will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + placebo in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence N will receive single dose of vofopitant 10 milligrams capsule in part 1, placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence O</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence O will receive placebo in part 1, single doses of lamotrigine 175 milligrams tablet + placebo in session A of part 2 and placebo + placebo in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence P</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence P will receive placebo in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + placebo in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence Q</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence Q will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session A of part 2 and placebo + placebo in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence R will receive single dose of vofopitant 10 milligrams capsule in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence S will receive placebo in part 1, single doses of lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session A of part 2 and placebo + placebo in session B of part 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on sequence T will receive placebo in part 1, single doses of placebo + placebo in session A of part 2 and lamotrigine 175 milligrams tablet + lamotrigine 150 milligrams tablet in session B of part 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose of placebo will be provided.</description>
    <arm_group_label>Treatment sequence J</arm_group_label>
    <arm_group_label>Treatment sequence C</arm_group_label>
    <arm_group_label>Treatment sequence P</arm_group_label>
    <arm_group_label>Treatment sequence N</arm_group_label>
    <arm_group_label>Treatment sequence S</arm_group_label>
    <arm_group_label>Treatment sequence I</arm_group_label>
    <arm_group_label>Treatment sequence L</arm_group_label>
    <arm_group_label>Treatment sequence R</arm_group_label>
    <arm_group_label>Treatment sequence F</arm_group_label>
    <arm_group_label>Treatment sequence B</arm_group_label>
    <arm_group_label>Treatment sequence G</arm_group_label>
    <arm_group_label>Treatment sequence D</arm_group_label>
    <arm_group_label>Treatment sequence H</arm_group_label>
    <arm_group_label>Treatment sequence T</arm_group_label>
    <arm_group_label>Treatment sequence A</arm_group_label>
    <arm_group_label>Treatment sequence M</arm_group_label>
    <arm_group_label>Treatment sequence K</arm_group_label>
    <arm_group_label>Treatment sequence E</arm_group_label>
    <arm_group_label>Treatment sequence Q</arm_group_label>
    <arm_group_label>Treatment sequence O</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vofopitant</intervention_name>
    <description>Vofopitant (GR205171) will be provided as 5 milligram single dose capsule administered orally. It will be available as swedish orange, size 0 capsules.</description>
    <arm_group_label>Treatment sequence J</arm_group_label>
    <arm_group_label>Treatment sequence C</arm_group_label>
    <arm_group_label>Treatment sequence P</arm_group_label>
    <arm_group_label>Treatment sequence N</arm_group_label>
    <arm_group_label>Treatment sequence S</arm_group_label>
    <arm_group_label>Treatment sequence I</arm_group_label>
    <arm_group_label>Treatment sequence L</arm_group_label>
    <arm_group_label>Treatment sequence R</arm_group_label>
    <arm_group_label>Treatment sequence F</arm_group_label>
    <arm_group_label>Treatment sequence B</arm_group_label>
    <arm_group_label>Treatment sequence G</arm_group_label>
    <arm_group_label>Treatment sequence D</arm_group_label>
    <arm_group_label>Treatment sequence H</arm_group_label>
    <arm_group_label>Treatment sequence T</arm_group_label>
    <arm_group_label>Treatment sequence A</arm_group_label>
    <arm_group_label>Treatment sequence M</arm_group_label>
    <arm_group_label>Treatment sequence K</arm_group_label>
    <arm_group_label>Treatment sequence E</arm_group_label>
    <arm_group_label>Treatment sequence Q</arm_group_label>
    <arm_group_label>Treatment sequence O</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
    <description>Lamotrigine will be provided as 25 milligrams or 100 milligrams single dose dispersible tablet administered orally.</description>
    <arm_group_label>Treatment sequence J</arm_group_label>
    <arm_group_label>Treatment sequence C</arm_group_label>
    <arm_group_label>Treatment sequence P</arm_group_label>
    <arm_group_label>Treatment sequence N</arm_group_label>
    <arm_group_label>Treatment sequence S</arm_group_label>
    <arm_group_label>Treatment sequence I</arm_group_label>
    <arm_group_label>Treatment sequence L</arm_group_label>
    <arm_group_label>Treatment sequence R</arm_group_label>
    <arm_group_label>Treatment sequence F</arm_group_label>
    <arm_group_label>Treatment sequence B</arm_group_label>
    <arm_group_label>Treatment sequence G</arm_group_label>
    <arm_group_label>Treatment sequence D</arm_group_label>
    <arm_group_label>Treatment sequence H</arm_group_label>
    <arm_group_label>Treatment sequence T</arm_group_label>
    <arm_group_label>Treatment sequence A</arm_group_label>
    <arm_group_label>Treatment sequence M</arm_group_label>
    <arm_group_label>Treatment sequence K</arm_group_label>
    <arm_group_label>Treatment sequence E</arm_group_label>
    <arm_group_label>Treatment sequence Q</arm_group_label>
    <arm_group_label>Treatment sequence O</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subject

          -  Male aged 18-65

          -  Greater than 50kg weight

          -  BMI 19-29.9 kg/m2

        Exclusion Criteria:

          -  Positive drug/alcohol screen

          -  Positive HIV antibody

          -  History of drug dependence

          -  History of neurological disease

          -  Pacemaker

          -  Smoker
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goettingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/112676?search=study&amp;study_ids=112676#rs</url>
    <description>Results for study 112676 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2009</study_first_submitted>
  <study_first_submitted_qc>May 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2009</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Resting motor threshold (rMT)</keyword>
  <keyword>Transcranial magnetic stimulation (TMS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
    <mesh_term>Vofopitant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>112676</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112676</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112676</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112676</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112676</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112676</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>112676</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

